{
    "nctId": "NCT05018676",
    "briefTitle": "ARX788 in Breast Cancer With Low Expression of HER2",
    "officialTitle": "A Single-arm, Single-center Phase II Clinical Study of Recombinant Humanized Anti-HER2 Monoclonal Antibody-AS269 Conjugate (ARX788) in the Treatment of Unresectable and/or Metastatic Breast Cancer With Low Expression of HER2",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer With Low Expression of HER2",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 54,
    "primaryOutcomeMeasure": "Objective remission rate (ORR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Willing and able to understand and sign an informed consent inform;\n* Age \u226518 years, and \u226475 years, male or female;\n* Diagnosed as HR arbitrary/HER2 low expression unresectable and/or metastatic breast cancer. HER2 low expression is defined as HER2 IHC 1+ (FISH negative or FISH not done) or HER2 IHC 2+ and FISH negative;\n* Received \u22652 lines of systemic chemotherapy regimens for recurrent or metastatic disease, and for HR positive subjects, also need to have received \u22652-line endocrine therapy \u00b1 targeted therapy (including neoadjuvant/adjuvant therapy);\n* Never had a HER2 positive result (IHC 3+ or FISH+) in previous pathological examinations;\n* Have archived or fresh tumor tissue samples for HER2 status confirmation;\n* According to the RECIST 1.1 standard, there is at least one measurable lesion;\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or1; LVEF\u226550%;\n* Adequate organ functions;\n* Acute toxicities from any prior therapy, surgery, or radiotherapy must have resolved to Grade \u22641;\n* Life expectancy \u2265 3 months.\n\nExclusion Criteria:\n\n* History of allergic reactions to any component of ARX788, or with a history of protein drug allergy, a history of specific allergies (asthma, rheumatism, eczematous dermatitis), or a history of other severe allergic reactions, who are unsuitable for ARX788 treatment as per the investigator's judgments;\n* Previous treatment with T-DM1 or other HER2-ADC drugs;\n* Have other malignant tumors within 5 years before signing the informed consent form (except for non-melanoma skin cancer, cervical carcinoma in situ or other tumors that have been effectively treated, except malignant tumors that are considered cured);\n* Have primary central nervous system (CNS) tumors or CNS metastases;\n* Prior history of interstitial pulmonary disease requiring hormone therapy, drug-induced interstitial pulmonary disease, radiation pneumonia, or current clinically active interstitial pulmonary disease;\n* Suffering from keratitis, corneal diseases, retinal diseases or active eye infections that require intervention;\n* Unwilling or unable to stop wearing contact lenses for the duration of the study;\n* Cardiac insufficiency;\n* Uncontrolled hypertension;\n* Suffering severe or uncontrolled systemic diseases;\n* Had chemotherapy, radiotherapy, or immunotherapy within 4 weeks before the first dose;\n* Had breast cancer endocrine therapy within 2 weeks before the first dose;\n* Had palliative radiotherapy for bone metastasis within 2 weeks before the first dose;\n* Any uncontrolled infection, or other conditions that may limit trial compliance or interfere with evaluation;\n* Current known active infection with human immunodeficiency virus (HIV), hepatitis B virus, hepatitis C virus or syphilis;\n* Plan to receive major surgical treatment within 2 weeks before first dose or during the trial period, or have suffered severe traumatic injury;\n* Pregnancy or lactation;\n* Unwilling or unable to use acceptable methods for contraception during the entire treatment period of this trial and within 8 months after the last dose;\n* Participated in other clinical trials and used other experimental drugs within 4 weeks before the first dose;\n* Any mental or cognitive impairment may limit their understanding and implementation of the informed consent form;\n* Not suitable for participating in this trial, such as poor compliance.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}